Skip to main content
Equibles
ACAD $19.89 -1.29%
ACAD logo
ACAD · Acadia Pharmaceuticals Inc
Track ACAD — free

Use ACAD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACAD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$19.89 -0.26 (-1.29%) At close · Oct 1
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$3.44B
Shares
172.31M
Volume · Oct 1 2.73M Avg daily vol (3M) 1.79M
All webcasts

Earnings call · FY2025 Q1

Acadia Pharmaceuticals Inc (ACAD) Q1 2025 Earnings Call

Concluded May 7, 2025
May 7, 2025 0 turns
Period
FY2025 Q1
Runtime
—
Sources
2 artifacts
8-K 10-Q

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.

DAYBUE commercial momentum and growth outlook 79 DAYBUE geographic expansion (Europe and rest of world) 44 NUPLAZID Parkinson's disease psychosis franchise 31 Pipeline advancement and R&D day 26 France ATU early access program 19 Financial guidance and gross-to-net dynamics 14

Management tone

Confident

Net tone +60 · low hedging

Grounding quotes
  • “We're off to a strong start in 2025. Our performance this quarter reflects solid execution across the business and continued momentum behind our strategic priorities.”
  • “This gives us confidence in the sustainability of DAYBUE's growth, and we reiterate our four-year sales guidance.”
  • “we have now started to see renewed growth in patients, and this gives us confidence that we will be able to accelerate growth in the second half of the year”
  • “We're also excited to host our first-ever R&D day next month that will offer a deeper look into our development strategy”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue $244.32M +18.7% YoY
Diluted EPS $0.11 +10% YoY
Net income $18.99M +14.7% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed May 7, 2025 10-Q report Filed May 8, 2025
Full-screen source Call document

ACAD transcript alerts

Acadia Pharmaceuticals Inc

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →